PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
This Quarter Return
-8.18%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$1.06B
AUM Growth
+$1.06B
(-15%)
Cap. Flow
-$10.2M
Cap. Flow
% of AUM
-0.97%
Top 10 Holdings %
Top 10 Hldgs %
88.26%
Holding
30
New
–
Increased
4
Reduced
4
Closed
1
Top Buys
| 1 |
NVRO
NEVRO CORP.
NVRO
|
$3.86M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$3.01M |
| 3 |
Gossamer Bio
GOSS
|
$2.55M |
| 4 |
NovoCure
NVCR
|
$1.33M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$11.7M |
| 2 |
Align Technology
ALGN
|
$5.77M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$2.03M |
| 4 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
$1.3M |
| 5 |
Vanda Pharmaceuticals
VNDA
|
$195K |
Sector Composition
| 1 | Healthcare | 98.08% |
| 2 | Financials | 1.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioMarin Pharmaceuticals
BMRN
$11.2B
| $162M | 15.33% | 1,831,035 | – | – |
|
2
Insmed
INSM
$28.8B
| $149M | 14.07% | 5,889,491 | – | – |
|
|
3
United Therapeutics
UTHR
$13.8B
| $130M | 12.31% | 575,907 -51,607 | -8% | -$11.7M |
|
4
Amicus Therapeutics
FOLD
$2.34B
| $128M | 12.11% | 10,524,022 | – | – |
|
5
Biogen
BIIB
$19.4B
| $98M | 9.27% | 381,282 | – | – |
|
6
Prothena Corp
PRTA
$441M
| $80M | 7.57% | 1,657,458 | – | – |
|
|
RVNC
7
DELISTED
Revance Therapeutics, Inc.
RVNC
| $60M | 5.67% | 5,228,609 | – | – |
|
8
STAAR Surgical
STAA
$1.36B
| $55.2M | 5.23% | 1,374,822 | – | – |
|
9
Acadia Pharmaceuticals
ACAD
$4.38B
| $50.1M | 4.74% | 2,405,793 | – | – |
|
|
SAGE
10
DELISTED
Sage Therapeutics
SAGE
| $20.7M | 1.96% | 1,005,776 +146,259 | +17% | +$3.01M |
|
11
eHealth
EHTH
$118M
| $20.3M | 1.92% | 2,739,379 | – | – |
|
|
12
Align Technology
ALGN
$10.3B
| $17M | 1.61% | 55,705 -18,900 | -25% | -$5.77M |
|
13
Alkermes
ALKS
$4.78B
| $16.9M | 1.6% | 603,400 | – | – |
|
14
Sarepta Therapeutics
SRPT
$1.78B
| $11.4M | 1.08% | 94,030 | – | – |
|
|
15
NovoCure
NVCR
$1.38B
| $10.7M | 1.01% | 660,275 +82,157 | +14% | +$1.33M |
|
16
AnaptysBio
ANAB
$569M
| $7.74M | 0.73% | 431,224 | – | – |
|
17
Karyopharm Therapeutics
KPTI
$61.7M
| $7.61M | 0.72% | 5,675,876 | – | – |
|
|
NVRO
18
DELISTED
NEVRO CORP.
NVRO
| $7.43M | 0.7% | 386,832 +200,573 | +108% | +$3.86M |
|
|
19
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.86M | 0.65% | 472,600 -140,000 | -23% | -$2.03M |
|
|
20
Gossamer Bio
GOSS
$562M
| $5.44M | 0.51% | 6,530,288 +3,065,136 | +88% | +$2.55M |
|
21
Cytokinetics
CYTK
$4.23B
| $3.29M | 0.31% | 111,717 | – | – |
|
22
Relmada Therapeutics
RLMD
$37.2M
| $2.2M | 0.21% | 732,400 | – | – |
|
23
Mirum Pharmaceuticals
MIRM
$3.71B
| $2.04M | 0.19% | 64,700 | – | – |
|
24
Travere Therapeutics
TVTX
$1.56B
| $1.48M | 0.14% | 166,069 | – | – |
|
|
25
Vanda Pharmaceuticals
VNDA
$279M
| $1.21M | 0.11% | 278,985 -45,088 | -14% | -$195K |
|